ArticleVeterinary and comparative oncology2018
Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
Article in Veterinary and comparative oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019-2023).Animals : an open access journal from MDPI · 2025Article
- Exposure-Response Relationships for Toceranib in Dogs with Solid Tumors: A Pilot Study.Animals : an open access journal from MDPI · 2025Article
- Osteosarcoma of the appendicular skeleton in dogs: consensus and guidelines.Frontiers in veterinary science · 2025Review
- COAnimals : an open access journal from MDPI · 2024Article
- An evaluation of the combination effect of zoledronate and chemotherapeutic agents in canine osteosarcoma cells.Frontiers in veterinary science · 2024Article
- A dog with extraskeletal osteosarcoma of the salivary glands survived long-term, following surgical resection and adjuvant therapy.The Journal of veterinary medical science · 2023Article
- Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs.Frontiers in immunology · 2023Review
- Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study.Veterinary medicine and science · 2023Article
- Repurposing Drugs in Small Animal Oncology.Animals : an open access journal from MDPI · 2022Review
- Characterizing the metabolic role of STAT3 in canine osteosarcoma.Veterinary and comparative oncology · 2022Article
- Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.International journal of molecular sciences · 2022Article
- Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.International journal of molecular sciences · 2022Review
- Feasibility and safety of whole lung irradiation in the treatment of canine appendicular osteosarcoma.Veterinary and comparative oncology · 2022Article
- C-kit, flt-3, PDGFR-β, and VEGFR2 expression in canine adrenal tumors and correlation with outcome following adrenalectomy.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2021Article
- The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.Veterinary and comparative oncology · 2021Article
- An Update on Molecular Pathways Regulating Vasculogenic Mimicry in Human Osteosarcoma and Their Role in Canine Oncology.Frontiers in veterinary science · 2021Review
- Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?Theranostics · 2021Review
- Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.Journal of veterinary internal medicine · 2020Article
- Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.Journal of veterinary internal medicine · 2020Article
- Recent and current clinical trials in canine appendicular osteosarcoma.The Canadian veterinary journal = La revue veterinaire canadienne · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Efficacious therapies for measurable metastatic canine osteosarcoma (OSA) are generally lacking. Preliminary retrospective studies suggested that approximately 50% of dogs with measurable metastatic OSA experienced clinical benefit (objective response or clinically meaningful disease stabilisation) following toceranib (TOC) treatment. The purpose of this clinical trial was to prospectively evaluate the clinical outcome following TOC treatment in dogs with measurable pulmonary metastatic OSA. A secondary goal was to identify potential biomarkers of clinical benefit by measuring changes in plasma vascular endothelial growth factor (VEGF) and circulating regulatory T-cell (Treg) percentage. Twenty-two dogs with pulmonary metastasis from appendicular OSA having undergone previous amputation were treated prospectively with TOC. Adverse events (AEs) were common but predominantly low grade. Nine patients were withdrawn from the study prior to the week 8 assessment of response either due to progressive disease (PD), decreased quality of life or owner perceived unacceptable AEs. Of the patients evaluable for disease progression at week 8 (or earlier), 3/17 (17.6 %) had stable disease with the remainder having PD. The median progression-free survival time for all patients was 57 days (range 7-176 days) with a median overall survival time of 89 days (range 7-574 days). Plasma VEGF concentrations were significantly elevated in patients after 4 weeks of TOC treatment, but no changes were observed in percentage of Treg in peripheral blood. Overall, the results of this clinical trial do not support the use of TOC as single agent therapy for canine metastatic OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.